Supreme Court Takes Up Appeal Of Post-Mensing Ruling
The U.S. Supreme Court agreed Friday to review the First Circuit's ruling that design defect claims against a generic-drug company are not preempted by federal law, a decision that critics charge...To view the full article, register now.
Already a subscriber? Click here to view full article